Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Belantamab Mafodotin with Bortezomib/Dexamethasone for R/R Myeloma
Global, randomised, open-label, phase 3 trial [DREAMM-7] Relapsed or refractory multiple myeloma after at least one line of therapy Belantamab-Bortezomib-dexamethasone (BVd) (n=243
New Drug: Telisotuzumab vedotin for cMET Amplified NSCLC
Phase 2, non-randomized, multicenter study (LUMINOSITY) Previously treated c-Met overexpressing NSQ EGFR wildtype advanced NSCLC (≤2 prior lines, ≤1 chemo) Telisotuzumab vedoti
New Drug: Penpulimab with Platinum – Gemcitabine in Advanced Nasopharyngeal Carcinoma
Global, multicenter, randomized, double-blind, phase 3 trial (AK105-304) Previously untreated recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) Penpulimab + gemcitabine/ci
New REference: Talazoparib and Enzalutamide for HRR-Deficient Prostate Cancer
Randomised, placebo-controlled, phase 3 trial [TALAPRO-2] Metastatic castration-resistant prostate cancer with HRR-deficiency Talazoparib+enzalutamide (n=200) vs enzalutamide+plac
New Reference: Advanced Pancreatic Cancer Protocols
Randomized, open-label, phase II/III trial [GENERATE, JCOG1611] Metastatic or recurrent pancreatic cancer mFOLFIRINOX (n=175) vs S-IROX (n=176) vs nab-paclitaxel gemcitabine (n=176
New Protocol: Brentuximab – ECADD Chemo for Hodgkin Lymphoma
Prospective, multicenter, single-arm, phase II cohort study [HD21 trial, NCT02661503] Older patients with advanced-stage classic Hodgkin lymphoma aged 61-75 years 4-6 cycles of PET
New Indication: Neoadjuvant Osimertinib with/without Chemo for NSCLC
Randomized, controlled, phase III study [NeoADAURA] NCT04351555 Resectable, EGFR-mutated, stage II-IIIB NSCLC Osimertinib+chemotherapy (n=121) vs Osimertinib (n=117) vs Placebo+che
New Protocol: Glofitamab with R-CHOP for High-Risk DLBCL
Phase II, open-label, multicenter study [COALITION; NCT04914741] Younger patients (≤65 years) with high-risk large B-cell lymphoma R-CHOP (n=40) vs Pola-R-CHP (n=40) with Glofi
New Protocol: Revumenib with Azacitidine and Venetoclax for KMT2-Rearranged / NPM1-Mutated
Phase I dose-escalation and expansion study [NCT03013998] First-line treatment for patients aged 60 years and older with newly diagnosed NPM1-mutated or KMT2A-rearranged AML Azac
